Goldman Sachs Maintains Neutral on Kestra Medical Techs, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 79.0%

Neg 79% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Kestra Medical Techs (NASDAQ:KMTS) with a Neutral and lowers the price target from $22 to $17.